CML 25 Years Later - Poised for Another Breakthrough?

MeSH terms

• Antineoplastic Agents* / administration & dosage
• Antineoplastic Agents* / adverse effects
• Antineoplastic Agents* / history
• Clinical Trials, Phase III as Topic
• Fusion Proteins, bcr-abl / antagonists & inhibitors
• Fusion Proteins, bcr-abl / genetics
• History, 20th Century
• History, 21st Century
• Humans
• Imatinib Mesylate / administration & dosage
• Imatinib Mesylate / adverse effects
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive* / drug therapy
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive* / genetics
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive* / history
• Niacinamide / administration & dosage
• Niacinamide / adverse effects
• Niacinamide / analogs & derivatives
• Pyrazoles / administration & dosage
• Pyrazoles / adverse effects
• Randomized Controlled Trials as Topic
• Treatment Outcome
• Tyrosine Kinase Inhibitors* / administration & dosage
• Tyrosine Kinase Inhibitors* / adverse effects
• Tyrosine Kinase Inhibitors* / history